PMC:7319613 / 5533-6236
Annnotations
LitCovid-PMC-OGER-BB
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T92 | 95-99 | G_3;PG_10;PR:000003622 | denotes | ACE2 |
T93 | 116-126 | GO:0010467 | denotes | expression |
T94 | 149-154 | G_3;PG_10;PR:000003622 | denotes | ACE-2 |
T95 | 191-201 | SP_7 | denotes | SARS-CoV-2 |
T96 | 265-270 | SP_6;NCBITaxon:9606 | denotes | human |
T97 | 282-295 | NCBITaxon:11118 | denotes | coronaviruses |
T98 | 306-316 | SP_7 | denotes | SARS-CoV-2 |
T99 | 335-339 | G_3;PG_10;PR:000003622 | denotes | ACE2 |
T100 | 349-359 | GO:0010467 | denotes | expression |
T101 | 379-383 | GO:0007567 | denotes | born |
T102 | 384-395 | NCBITaxon:1 | denotes | individuals |
T103 | 420-428 | SP_7 | denotes | COVID-19 |
T104 | 504-508 | G_3;PG_10;PR:000003622 | denotes | ACE2 |
T105 | 589-593 | CHEBI:23888;CHEBI:23888 | denotes | drug |
T106 | 628-638 | CHEBI:35222;CHEBI:35222 | denotes | inhibitors |
T107 | 646-660 | DG_37 | denotes | angiotensin II |
T108 | 698-702 | G_3;PG_10;PR:000003622 | denotes | ACE2 |
T38487 | 95-99 | G_3;PG_10;PR:000003622 | denotes | ACE2 |
T29778 | 116-126 | GO:0010467 | denotes | expression |
T5033 | 149-154 | G_3;PG_10;PR:000003622 | denotes | ACE-2 |
T62086 | 191-201 | SP_7 | denotes | SARS-CoV-2 |
T5970 | 265-270 | SP_6;NCBITaxon:9606 | denotes | human |
T62135 | 282-295 | NCBITaxon:11118 | denotes | coronaviruses |
T78198 | 306-316 | SP_7 | denotes | SARS-CoV-2 |
T26439 | 335-339 | G_3;PG_10;PR:000003622 | denotes | ACE2 |
T83020 | 349-359 | GO:0010467 | denotes | expression |
T28084 | 379-383 | GO:0007567 | denotes | born |
T9860 | 384-395 | NCBITaxon:1 | denotes | individuals |
T70597 | 420-428 | SP_7 | denotes | COVID-19 |
T86139 | 504-508 | G_3;PG_10;PR:000003622 | denotes | ACE2 |
T70794 | 589-593 | CHEBI:23888;CHEBI:23888 | denotes | drug |
T66606 | 628-638 | CHEBI:35222;CHEBI:35222 | denotes | inhibitors |
T7504 | 646-660 | DG_37 | denotes | angiotensin II |
T88363 | 698-702 | G_3;PG_10;PR:000003622 | denotes | ACE2 |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T13 | 202-206 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
T14 | 243-247 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T27 | 191-199 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T28 | 306-314 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T29 | 420-428 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T30 | 564-576 | Disease | denotes | hypertension | http://purl.obolibrary.org/obo/MONDO_0005044 |
T31 | 580-588 | Disease | denotes | diabetes | http://purl.obolibrary.org/obo/MONDO_0005015 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T24 | 100-108 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
T25 | 142-146 | http://purl.obolibrary.org/obo/CLO_0001185 | denotes | 2018 |
T26 | 202-206 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cell |
T27 | 243-247 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cell |
T28 | 265-270 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | human |
T29 | 340-348 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
T30 | 448-451 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
T31 | 509-517 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T9 | 589-593 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
T10 | 624-638 | Chemical | denotes | ACE inhibitors | http://purl.obolibrary.org/obo/CHEBI_35457 |
T11 | 628-638 | Chemical | denotes | inhibitors | http://purl.obolibrary.org/obo/CHEBI_35222 |
T12 | 646-660 | Chemical | denotes | angiotensin II | http://purl.obolibrary.org/obo/CHEBI_2719|http://purl.obolibrary.org/obo/CHEBI_48432|http://purl.obolibrary.org/obo/CHEBI_58506 |
T15 | 646-657 | Chemical | denotes | angiotensin | http://purl.obolibrary.org/obo/CHEBI_48433 |
T16 | 658-660 | Chemical | denotes | II | http://purl.obolibrary.org/obo/CHEBI_74067 |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
121 | 95-99 | Gene | denotes | ACE2 | Gene:59272 |
122 | 149-154 | Gene | denotes | ACE-2 | Gene:59272 |
123 | 335-339 | Gene | denotes | ACE2 | Gene:59272 |
124 | 504-508 | Gene | denotes | ACE2 | Gene:59272 |
125 | 624-627 | Gene | denotes | ACE | Gene:1636 |
126 | 698-702 | Gene | denotes | ACE2 | Gene:59272 |
127 | 191-201 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
128 | 265-270 | Species | denotes | human | Tax:9606 |
129 | 282-295 | Species | denotes | coronaviruses | Tax:11118 |
130 | 306-316 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
131 | 420-428 | Disease | denotes | COVID-19 | MESH:C000657245 |
132 | 564-576 | Disease | denotes | hypertension | MESH:D006973 |
133 | 580-588 | Disease | denotes | diabetes | MESH:D003920 |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T22 | 564-576 | Phenotype | denotes | hypertension | http://purl.obolibrary.org/obo/HP_0000822 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T34 | 0-148 | Sentence | denotes | Finally, accumulating evidence indicates that prematurity might also be associated with higher ACE2 activity and/or expression (South et al., 2018). |
T35 | 149-317 | Sentence | denotes | ACE-2 is known to be directly involved in SARS-CoV-2 cell-binding, representing the main host cell receptor for all human pathogenic coronaviruses including SARS-CoV-2. |
T36 | 318-438 | Sentence | denotes | Thus, the higher ACE2 activity/expression in the prematurely born individuals might result in greater COVID-19 severity. |
T37 | 439-703 | Sentence | denotes | One also has to bear in mind that the prematurity-related higher ACE2 activity might be additionally heightened by potential hypertension or diabetes drug therapies which often include ACE inhibitors and/or angiotensin II receptor blockers, both upregulating ACE2. |